E
CLVS

Ergoteles’s Clovis Oncology, Inc. CLVS Stock Holding History

Ergoteles’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-707,300
Closed -$1.27M – 2186
2022
Q2 		$1.27M Buy
+707,300
New +$1.04M 0.04% 440
2022
Q1 		– Sell
-171,878
Closed -$466K – 1755
2021
Q4 		$466K Buy
171,878
+102,289
+147% +$378K 0.02% 671
2021
Q3 		$310K Buy
+69,589
New +$335K 0.01% 785

Other funds holding CLVS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ergoteles's CLVS Position: Q3 2022 in Review

Ergoteles sold out of Clovis Oncology, Inc. (CLVS) in Q3 2022, closing a stake of 707,300 shares — an estimated $1.27M sold.

Ergoteles first reported a position in CLVS in Q3 2021 and held it in 3 quarters. The position peaked at $1.27M in Q2 2022. 103 funds tracked by Wall St. Rank hold CLVS as of Q3 2022.

  • Ergoteles reported no remaining Clovis Oncology, Inc. position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 707,300 Clovis Oncology, Inc. shares in Q3 2022, an estimated $1.27M.
  • Ergoteles first reported a position in Clovis Oncology, Inc. in Q3 2021 and held it in 3 quarters.
  • Ergoteles's Clovis Oncology, Inc. position peaked at $1.27M in Q2 2022.
  • 103 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.